All In Biotech

Drug Trial Radar · NCT04701983

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,127

Actual

Start

Dec 16, 2020

Primary completion

Apr 11, 2025

Study completion Aug 27, 2025

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jan 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: * Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on occurrence of acute exacerbation of COPD (AECOPD) in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on severe AECOPD in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on corticosteroid-treated AECOPD in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on respiratory symptoms in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on Forced Expiratory Volume in 1 second (FEV1) slope in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on health-related quality of life (HRQoL) as assessed by St. George's Respiratory Questionnaire (SGRQ) in former smokers with moderate-to-severe COPD * Evaluate the safety and tolerability of itepekimab in former smokers with moderate-to-severe COPD * Evaluate the pharmacokinetic (PK) profile of itepekimab in former smokers with moderate-to-severe COPD * Evaluate immunogenicity to itepekimab in former smokers with moderate-to-severe COPD

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Itepekimab SAR440340Drug

    * Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous

  • PlaceboDrug

    * Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Events Over the Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Week 24 to 52 for additional randomized participants

Locations

232 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Site Number : 8400012

    Birmingham, Alabama

  • Jasper Summit Research Site Number : 8400178

    Jasper, Alabama

  • Chandler Clinical Trials (Elite Clinical Network) Site Number : 8400034

    Chandler, Arizona

  • Pulmonary Associates Site Number : 8400392

    Phoenix, Arizona

  • Noble Clinical Research Site Number : 8400182

    Tucson, Arizona

  • Tucson Clinical Research Institute Site Number : 8400431

    Tucson, Arizona

  • California Research Institute Site Number : 8400400

    Huntington Park, California

  • Modena Allergy + Asthma Site Number : 8400036

    La Jolla, California

  • Imax Clinical Trials LLC 1 Site Number : 8400419

    La Palma, California

  • Downtown LA Research Center Inc. Site Number : 8400027

    Los Angeles, California

  • MACRO Trials Site Number : 8400030

    Los Angeles, California

  • Antelope Valley Clinical Trials Site Number : 8400003

    Northridge, California

  • ~Alpine Clinical Research Center Site Number : 8400180

    Boulder, Colorado

  • Innovative Clinical Research Site Number : 8400017

    Lafayette, Colorado

  • Clin Research W Florida Site Number : 8400004

    Clearwater, Florida

  • Beautiful Minds Clinical Research Center Site Number : 8400037

    Cutler Bay, Florida

  • Indago Research and Health Center Site Number : 8400187

    Hialeah, Florida

  • Advanced Clinical Research Site Number : 8400409

    Kendall, Florida

  • Advanced Pulmonary Research Institute Site Number : 8400455

    Loxahatchee Groves, Florida

  • University of Miami/Miami VA Medical Center Site Number : 8400026

    Miami, Florida

  • DL Research Solutions Inc Site Number : 8400033

    Miami, Florida

  • Reliant Medical Research Site Number : 8400397

    Miami, Florida

  • Research Institute of South Florida,Inc Site Number : 8400006

    Miami, Florida

  • PROLIVE MEDICAL RESEARCH Site Number : 8400420

    Miami, Florida

  • Reed Medical Research Site Number : 8400032

    Miami, Florida

  • High Quality Research Site Number : 8400406

    Miami, Florida

  • Deluxe Health Center Site Number : 8400188

    Miami Lakes, Florida

  • Florida Institute for Clinical Research Site Number : 8400013

    Orlando, Florida

  • Tellabio International Research Services Site Number : 8400411

    Pembroke Pines, Florida

  • Avanza Medical Research Center Site Number : 8400376

    Pensacola, Florida

  • Broward Pulmonary and Sleep Specialists Site Number : 8400031

    Plantation, Florida

  • Coastal Medical Research Institute Site Number : 8400044

    St. Petersburg, Florida

  • Pasadena Center for Medical Research Site Number : 8400043

    St. Petersburg, Florida

  • AdtreMed Site Number : 8400442

    Tampa, Florida

  • Premier Medical Associates Site Number : 8400388

    The Villages, Florida

  • Appalachian Clinical Research Site Number : 8400024

    Adairsville, Georgia

  • Covenant Pulmonary Critical Care Site Number : 8400183

    Atlanta, Georgia

  • David Kavtaradze MD, Inc. Site Number : 8400029

    Cordele, Georgia

  • Alpha Clinical Research Georgia Site Number : 8400190

    Dunwoody, Georgia

  • Gwinnett Biomedical Research Site Number : 8400007

    Lawrenceville, Georgia

Showing 40 of 232 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.